NovaBay Pharmaceuticals, Inc. (NBY) Balance Sheet

The consistent decline in total assets suggests that the company is liquidating or consuming its resource base to fund ongoing operating losses. This trajectory indicates that the firm is rapidly losing the capacity to support its commercial activities without significant external intervention.

While the current ratio of 2.00 appears superficially adequate, the underlying cash burn rate suggests that this liquidity buffer is likely transient. Investors should monitor the company's ability to manage short-term liabilities, as the current cash position provides little margin for error in a high-burn environment.

The persistent accumulation of losses has effectively wiped out the value attributable to shareholders, leaving the equity base highly sensitive to further operational underperformance. This trend suggests that the company's capital structure is fundamentally impaired and may require significant restructuring to restore long-term viability.

The presence of $970,000 in debt against a backdrop of negative retained earnings implies that the company's leverage is a symptom of financial distress. This reliance on debt financing in the face of declining assets warrants further investigation into the sustainability of the firm's current capital structure.